Translating groundbreaking science into tomorrow’s cures

Explore our science
Announcement

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

May 5, 2022 at 4:30 PM EDT

Event Details

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline
Patient Stories

Read Sharron’s
inspiring story
of kidney
transplantation

View Elizabeth's Story
Patient, Liz
The Latest at Sangamo
Latest Publications & Presentations
All Publications
All Presentations

Our Pipeline

Phase 3
  • Hemophilia A

    Giroctocogene Fitelparvovec

    Sangamo Logo
    |
  • Gene therapy
  • Cell therapy
  • Genome engineering
Phase 1/2
  • Fabry Disease

    Isaralgagene civaparvovec

    Sangamo Logo
  • Renal Transplant

    (Autologous)
    TX200

    Sangamo Logo
  • Sickle Cell Disease*

    SAR445136

    Sangamo Logo
    |
Preclinical
  • Inflammatory Bowel Disease
    Sangamo Logo
  • Renal Transplant

    (Allogeneic)

    Sangamo Logo
  • Multiple Sclerosis
    Sangamo Logo
  • Prion
    Sangamo Logo
  • Neurology

    Undisclosed

    Sangamo Logo
  • Oncology

    KITE-037

    Sangamo Logo
    |
  • Oncology

    Undisclosed

    Sangamo Logo
    |
  • Neuro- developmental Disorders
    Sangamo Logo
    |
  • ALS/FTD
    Sangamo Logo
    |
  • Huntington’s Disease
    Sangamo Logo
    |
  • a-Synuclein

    ST-502

    Sangamo Logo
    |
  • Tauopathies

    ST-501

    Sangamo Logo
    |
  • Neurology

    DMI

    Sangamo Logo
    |
  • Neurology

    Undisclosed

    Sangamo Logo
    |

*Transitioning to wholly owned program in June 2022